Lancet accuses AstraZeneca of sponsoring biased research

The Lancet last week took the unprecedented step of accusing Europe's second biggest drug company, AstraZeneca, of sponsoring biased research into its new anticholesterol drug rosuvastatin (Crestor).

Dr Richard Horton: doctors “must tell their patients the truth about rosuvastatin”

In an editorial, the journal's editor, Richard Horton, said the company's tactics “raise disturbing questions about how drugs enter clinical practice and what measures exist to protect patients from inadequately investigated medicines”(Lancet 2003;362: 1341).

The Galaxy series …